HIV DNA vaccine (FIT Biotech/IAVI)

(GTU MultiHIV^®) Phase II Active

A vaccine potentially for the prevention and treatment of HIV infection.

Research Code FIT-06

CAS No.

Recombinant acellular pertussis vaccine (BioNet-Asia)

(Viaskin rPT, Viaskin-PT ^®) Approved

A recombinant acellular pertussis vaccine used to prevent of pertussis.

Research Code

CAS No.

Anti-MUC1 monoclonal antibody (OncoQuest)

(BrevaRex^®) Phase II Active

A mucin 1 (MUC1) targeted antibody potentially for the treatment for pancreatic cancer.

Research Code Anti-MUC1 AR20.5; AR20.5; mAb-AR20.5

CAS No.

Hib CRM197 vaccine conjugate

(HibTITER^®) Withdrawn

A Haemophilus influenzae type B (Hib) and CRM197 conjugate vaccine usd to prevent Hib infection.

Research Code MT-2301; NU-300

CAS No.

Dendritic cell vaccine (Medigene)

Phase II Active

An autologous dendritic cell-based vaccine potentially for the treatment of prostate cancer and acute myeloid leukaemia.

Research Code IL-12p70 DC vaccine

CAS No.

QR-333

Phase II Discontinued

An antioxidant potentially for the treatment of diabetic neuropathy.

Research Code QR-333

CAS No.

ICX-PRO

Phase III Discontinued

A drug potentially for the treatment of varicose ulcer.

Research Code ICX-PRO; ICXP-007

CAS No.

P-128

(StaphTAME^®) Phase II Active

A recombinant protein potentially for the treatment of staphylococcal infection.

Research Code P-128

CAS No.

Namirotene

Phase II Discontinued

A protein synthesis inhibitor potentially for the treatment of corneal ulcer and dry eyes.

Research Code CBS-211A

CAS No. 101506-83-6(Namirotene)

Icoduline Hydrochloride

Phase III Discontinued

A 5-lipoxygenase (5-LOX)/cyclooxygenase (COX) inhibitor potentially for the treatment of eye disorders.

Research Code CBS-113A

CAS No. 110952-54-0(CBS-113A)  138511-81-6(Icoduline)

Talmetacin

NDA Filing Pending

A cyclooxygenase (COX) inhibitor potentially for the treatment of rheumatic disorders.

Research Code BA-760506; PV-102

CAS No. 67489-39-8(Talmetacin)

Cal 1-transduced haematopoietic stem progenitor cell

Phase II Active

A gene therapy potentially for the treatment of HIV infection.

Research Code CAL-1; CAL-MGMT; LVsh5C46; VIP

CAS No.

Influenza A virus H1N1 vaccine (iBio)

Phase I Pending

A vaccine potentially for the prevention of influenza A virus H1N1 subtype infection.

Research Code

CAS No.

PA-83-FhCMB

Phase I Active

A plant derived recombinant protective antigen vaccine potentially for the prevention of anthrax.

Research Code PA-83-FhCMB; PA83-FhCMB

CAS No.

Influenza A virus vaccine H5N1 (iBio)

Phase I Active

A vaccine for the prevention of influenza A virus H5N1 infection.

Research Code

CAS No.

Anti-EphA3 MAb

Phase II Active

A EphA3 targeted antibody potentially for the treatment of acute myeloid leukaemia, myelodysplastic syndromes and myelofibrosis.

Research Code KB-004

CAS No.

Anti-PcrV mAb fragment

Phase II Discontinued

An anti-PcrV pegylated antibody fragment potentially for the prevention of nosocomial pneumonia and pseudomonal infections.

Research Code KB-001; KB-001A

CAS No.

Lenzilumab

Phase II Active

A granulocyte macrophage colony stimulating factor antagonist potentially for the treatment of chronic myelomonocytic leukaemia.

Research Code KB-003

CAS No. 1229575-09-0

GLS-5300

Phase I Active

A DNA vaccine potentially for the prevention of middle-east respiratory syndrome virus infection.

Research Code GLS-5300

CAS No.

VGX-3400

Phase I Active

A DNA prophylactic vaccine potentially for the prevention of influenza A virus H5N1 subtype and H1N1 subtype infection.

Research Code VGX-3400; VGX-3400X

CAS No.